Everolimus has shown efficacy in breast cancer by inhibiting cell growth through downregulation of the PI3K/Akt/mTOR signaling pathway, highlighting its potential as a therapeutic option for primary breast AS (122). Here, AKT1 is linked to breast carcinoma.